March 09, 2022 – Casablanca – UGGC Africa has advised Pharmaceutical Institute on its acquisition by KELIX bio, a pan-African biopharmaceutical platform. This investment marks KELIX bio’s first entry into Morocco – an important market in the company’s strategy – at a time when the Kingdom is accelerating the successful rollout of AMO (Assurance Maladie Obligatoire), a far-reaching plan to provide universal health coverage to Moroccans.
UGGC Africa advised Pharmaceutical Institute (PHI) with Laurent Sablé (partner).
Sijilmasa Ltd (Mr. Amine Rezzouk) acted on the financial aspects and Naciri & Associés Allen & Overy as legal counsel.